Rac H, et al. - In this study, the susceptibility of mucoid Pseudomonas aeruginosa (MP) strains to ceftolozane/tazobactam was examined, as well as the efficacy of ceftolozane/tazobactam against MP strains compared with those for standard-of-care antipseudomonal antibiotics. Findings demonstrated that at both the 1.5-g dose and the 3-g dose, ceftolozane/tazobactam activity against MP strains derived from cystic fibrosis (CF) patients was comparable to that of standard-of-care agents.